Wegovy’s new pricing could save you $1,200—but it’s not for everyone

Novo Nordisk just launched a new subscription program for Wegovy customers.  In an announcement Tuesday, the Danish GLP-1 maker said the new program will help “reduce cost uncertainty” so that people can maintain access to their obesity drugs. Wegovy contains semaglutide, a glucagon-like peptide-1 receptor agonist used for chronic weight management. Novo Nordisk also promised savings of up to $600 per year for the pill form of the drug and up to $1,200 per year for the injections with a 12-month subscription. Eligible patients can choose the self-pay options that work best for them. A three-month plan will cost users $329 per month. A six-month plan is $299 per month. And a 12-month subscription comes with a monthly fee of just $249. “The new Wegovy subscription program removes barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment,” said Ed Cinca, senior vice president, Marketing